NCT02514083View on ClinicalTrials.gov

A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

December 9, 2015

Primary Completion Date

October 2, 2019

Study Completion Date

October 23, 2034

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
DRUG

Ibrutinib

Ibrutinib 420mg PO daily for the duration of the study.

DRUG

Fludarabine

Fludarabine 25 mg/m2/day IV on days 1-5 of cycles 3 and 4

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH